Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.
General Instructions provides useful general background information for successfully completing forms.
2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.
Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.
Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.
Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.
Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms
Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.
Appendices provide additional information beyond the scope of the other manuals.
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
|12/6/17||2028: Aplastic Anemia Pre-HCT||Add|| Added the following instruction for question 31.
If this is a report of a second or subsequent transplant for aplastic anemia and this baseline disease insert has previously been completed for a prior transplant, indicate if the recipient received treatment for aplastic anemia between Day 0 of the previous HCT and the start of the preparative regimen for the subsequent HCT.
|11/21/17||2010: AML Pre-Infusion Data||Modify|| Corrected incorrect instruction provided for questions 6-9. The form asks for cytotoxic therapy; however, the manual incorrectly instructed centers to report any systemic therapies.
|11/20/17||2100: Post-HCT Follow-Up||Modify|| Added (in red) and removed (struck out) text from description of IPn / ARDS provided in the instructions for questions 441-485.
IPn refers to inflammation of the alveolar walls. Acute respiratory distress syndrome typically refers to fluid build-up within the alveoli. In either case, gas exchange is impaired resulting in oxygen deprivation. Both conditions can result from infectious or non-infectious causes.
|11/20/17||2100: Post-HCT Follow-Up||Add|| Added instructions below for question 158.
If the date of diagnosis is unknown, leave question 158 blank and override the validation error using the code “Unknown.” However, question 158 may not be left blank if treatment for acute GVHD (question 185) is reported “Yes.” If the exact clinical diagnosis date is unknown, but the treatment start date is known, report the date treatment started as the date of acute GVHD diagnosis.
|11/15/17||4100: Cellular Therapy Essential Data Follow-Up||Modify|| Replaced description of grade 4 organ toxicity provided in the instructions for Questions 82-138.
Grade 4 organ toxicity: As defined by the CTCAE criteria , grade 4 toxicity represents life-threatening consequences and urgent intervention is indicated
|11/15/17||4000: Cellular Therapy Essential Data Pre-Infusion||Modify|| Replaced instructions for question 35 as indicated below.
Indicate whether the cellular therapy product reported in this instance contains Cytotoxic T Lymphocytes (CTLs). These products are generally from allogeneic donors that have been cultured / expanded and modified to treat specific viruses such as CMV, EBV, Adenovirus, etc.
|11/15/17||2100: Post-HCT Follow-Up||Add|| Added the fungal infection codes below to the list of infections which will prompt the Fungal Infection Post-HCT Form to come due. The list is provided in the instructions for questions 428-436.